Home Cart Sign in  
Chemical Structure| 2070015-25-5 Chemical Structure| 2070015-25-5

Structure of EPZ020411 HCl
CAS No.: 2070015-25-5

Chemical Structure| 2070015-25-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

EPZ020411 hydrochloride is a selective PRMT6 inhibitor with an IC50 of 10 nM, exhibiting over 10-fold selectivity against PRMT1 and PRMT8. EPZ020411 hydrochloride can be used in cancer research.

Synonyms: EPZ020411 2HCl; EPZ020411 hydrochloride

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of EPZ020411 HCl

CAS No. :2070015-25-5
Formula : C25H39ClN4O3
M.W : 479.06
SMILES Code : CNCCN(C)CC1=CNN=C1C2=CC=C(O[C@H]3C[C@H](OCCC4CCOCC4)C3)C=C2.[H]Cl
Synonyms :
EPZ020411 2HCl; EPZ020411 hydrochloride
MDL No. :MFCD29924736

Safety of EPZ020411 HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of EPZ020411 HCl

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEI-OC1 cells 30 μM 24 h To assess the effect of PRMT6 knockdown on cisplatin-induced apoptosis in HEI-OC1 cells. Results showed that PRMT6 knockdown significantly reduced cisplatin-induced apoptosis and ROS accumulation. PMC6929624
Mouse cochlear explants 20 μM and 40 μM 6 h To evaluate the protective effect of EPZ020411 against aminoglycoside- and cisplatin-induced hair cell damage. Results showed that EPZ020411 pretreatment significantly reduced hair cell apoptosis and increased hair cell survival. PMC6929624
GSC23 20 μM 12 h EPZ decreased the levels of RCC1 R214me2 and H3R2me2, reduced the association of RCC1 with chromatin, increased the frequency of mitotic and interphase defects, induced cell cycle arrest (p21 induction), and blocked mitotic progression (p-S10H3 reduction). PMC7979509
GSC576 20 μM 12 h EPZ decreased the levels of RCC1 R214me2 and H3R2me2, reduced the association of RCC1 with chromatin, increased the frequency of mitotic and interphase defects, induced cell cycle arrest (p21 induction), and blocked mitotic progression (p-S10H3 reduction). PMC7979509
CT26 4 µM 4 weeks Long-term EPZ020411 treatment induced an MSI-like phenotype in CT26 cells, with impaired MMR activity. PMC11907083
SW480 4 µM 24 h To evaluate the effect of EPZ020411 on MMR activity in SW480 cells, results showed that EPZ020411 treatment reduced MMR activity. PMC11907083
MDA-MB-468 20 µM EPZ020411 inhibits PRMT6 activity, reduces asymmetric dimethylation (ADMA) levels of STAT3, thereby inhibiting Y705 phosphorylation of STAT3. PMC10562413
MCF-7 20 µM EPZ020411 inhibits PRMT6 activity, reduces asymmetric dimethylation (ADMA) levels of STAT3, thereby inhibiting Y705 phosphorylation of STAT3. PMC10562413
LN229 cells 20 μM 48 h Inhibited PRMT6 activity, reduced CDC20 and H3R2me2a expression, increased CDKN1B expression, leading to cell cycle arrest at G0/G1 phase PMC10063447
U87 cells 20 μM 48 h Inhibited PRMT6 activity, reduced CDC20 and H3R2me2a expression, increased CDKN1B expression, leading to cell cycle arrest at G0/G1 phase PMC10063447

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Aminoglycoside- and cisplatin-induced ototoxicity models Trans-tympanic injection 10 mM Single injection To evaluate the protective effect of EPZ020411 against aminoglycoside- and cisplatin-induced hearing loss in vivo. Results showed that EPZ020411 pretreatment significantly attenuated hearing loss and hair cell damage. PMC6929624
Ncr nu/nu mice GBM brain tumor xenografts Subcutaneous administration 10 mg/kg Daily for three weeks EPZ enhanced the effects of IR in decreasing GSC viability and sphere-forming frequency, markedly reduced RCC1me2 levels, with or without IR. Co-administration of EPZ significantly enhanced the cytotoxic activity of IR, as indicated by significant increases in animal survival. PMC7979509
Mice AOM/DSS-induced CRC model Intraperitoneal injection 10 mg/kg Once daily for 5 weeks To evaluate the therapeutic effect of EPZ020411 on AOM/DSS-induced CRC model, results showed that EPZ020411 treatment reduced the number and size of colon tumors. PMC11907083
C57BL/6J mice HSV-1-induced PHN model Intrathecal and intraperitoneal 1 μg/5 μl (intrathecal), 10 mg/kg (intraperitoneal) Three consecutive days To evaluate the therapeutic effect of EPZ020411 on HSV-1-induced neuroinflammation and PHN. EPZ020411 reduced neuroinflammation and PHN by enhancing antiviral innate immunity and decreasing HSV-1 load. PMC11224619
Female nude mice Breast cancer lung metastasis model Subcutaneous injection 10 mg/kg Daily until the end of the experiment EPZ020411 significantly reduced the number of lung metastasis nodules, extended the overall survival time of mice, and inhibited STAT3 methylation and phosphorylation. PMC10562413

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.09mL

0.42mL

0.21mL

10.44mL

2.09mL

1.04mL

20.87mL

4.17mL

2.09mL

References

 

Historical Records

Categories